Search

Displaying results 4341 - 4350 of 10000 in total
  1. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  2. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    It is currently approved in South Africa under the tradename Roxit.

  3. Drug

    Sodium lauryl sulfoacetate

    go.drugbank.com/drugs/DB13157
    ApprovedWithdrawn

    Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.

  4. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

  5. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  6. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  7. Drug

    Calanolide A

    go.drugbank.com/drugs/DB04886
    Investigational

    Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity.

  8. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  9. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Categories: Vasodilators Used in Cardiac DiseasesSynonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
  10. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.